To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Leqselvi

Deuruxolitinib
Immunomodulators
Oral Tablets

Leqselvi is an oral tablet prescribed for adults with severe alopecia areata, a condition that causes widespread hair loss. It works by blocking specific Janus kinase enzymes involved in the autoimmune process, leading to significant hair regrowth over 30% of patients saw at least 80% scalp coverage in clinical trials

Approval Date
25-Jul-24
NCE-1 Date
25-Jul-28
NCE Date
25-Jul-29
Commercial snapshot

Market performance & projections

Revenue ($M)
NA
CAGR (%)
NA
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
51
2027
91
2028
124
2029
159
2030
194
2031
229
2032
264
Molecule profile

Details & specifications

Molecule
Deuruxolitinib
Innovator
SUN PHARMACEUTICAL INDUSTRIES INC
Dosage Form
Oral Tablets
Strength
8 mg
Therapeutic Category
Immunomodulators
Usage
To treat severe alopecia areata
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?